10,700 Shares in Vericel Corporation $VCEL Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Vericel Corporation (NASDAQ:VCEL) in the 3rd quarter, HoldingsChannel reports. The fund bought 10,700 shares of the biotechnology company’s stock, valued at approximately $429,000.

Several other hedge funds also recently made changes to their positions in the company. Choreo LLC raised its position in shares of Vericel by 69.9% during the 3rd quarter. Choreo LLC now owns 10,993 shares of the biotechnology company’s stock valued at $441,000 after acquiring an additional 4,521 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Vericel by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,343 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 1,215 shares during the last quarter. Gibbs Wealth Management boosted its holdings in Vericel by 7.2% in the third quarter. Gibbs Wealth Management now owns 26,205 shares of the biotechnology company’s stock worth $1,052,000 after purchasing an additional 1,751 shares during the period. Inspire Investing LLC acquired a new position in Vericel in the third quarter worth $633,000. Finally, Kopp Family Office LLC boosted its holdings in Vericel by 0.6% in the third quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock worth $2,061,000 after purchasing an additional 299 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a research note on Thursday, July 30th. HC Wainwright raised their price target on shares of Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday. TD Cowen lifted their price target on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Vericel from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Truist Financial set a $65.00 price objective on shares of Vericel in a research report on Friday. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $60.80.

Vericel News Summary

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Insiders Place Their Bets

In other Vericel news, Director Robert Zerbe sold 3,000 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $52.23, for a total value of $156,690.00. Following the sale, the director directly owned 32,995 shares of the company’s stock, valued at $1,723,328.85. This trade represents a 8.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Flynn sold 15,000 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total value of $778,800.00. Following the completion of the sale, the insider owned 1,990 shares in the company, valued at $103,320.80. The trade was a 88.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 22,000 shares of company stock valued at $1,128,340 over the last three months. Company insiders own 7.60% of the company’s stock.

Vericel Trading Up 5.5%

Shares of Vericel stock opened at $54.62 on Friday. The business’s 50 day simple moving average is $41.01 and its 200-day simple moving average is $38.90. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $55.60.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a return on equity of 9.09% and a net margin of 10.27%. The business had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. During the same quarter last year, the business posted $0.10 EPS. The business’s revenue was up 26.5% on a year-over-year basis. Sell-side analysts predict that Vericel Corporation will post 0.54 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.